STOCK TITAN
  1. Home
  2. News
  3. PXMD

PAXMEDICA INC - PXMD STOCK NEWS

Welcome to our dedicated page for PAXMEDICA news (Ticker: PXMD), a resource for investors and traders seeking the latest updates and insights on PAXMEDICA stock.

PaxMedica, Inc. (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focusing on the development of innovative anti-purinergic drug therapies (APT) for treating challenging neurological disorders. The company's primary focus is on Autism Spectrum Disorder (ASD) and Human African Trypanosomiasis (HAT). Through its pioneering drug program, PAX-101, an intravenous suramin formulation, PaxMedica aims to provide effective treatment solutions for these conditions.

PaxMedica's recent achievements include the completion of three pivotal registration/validation batches of PAX-101. This milestone is crucial for the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), planned for the fourth quarter of 2024. If approved, PAX-101 will become the first and only form of suramin available in the U.S. for treating Stage 1 HAT, a fatal disease caused by Trypanosoma brucei rhodesiense.

In response to an urgent request from the Ministry of Health in Malawi, PaxMedica has expedited the provision of PAX-101 to address a critical shortage of medications for treating HAT. This initiative highlights the company's commitment to addressing global health crises and ensuring a steady supply of essential drugs.

The company's research efforts extend beyond ASD and HAT, exploring potential therapeutic applications for related neurologic conditions. PaxMedica aims to advance its clinical trials and develop treatments that target the core symptoms of ASD, providing hope and support to millions of affected individuals and their families.

Financially, PaxMedica recently announced a public offering, raising approximately $7.0 million. The funds are intended to repay outstanding debts, advance development programs, and support general corporate purposes. Additionally, the company has transitioned off the NASDAQ stock market, emphasizing that this change will not affect its commitment to advancing treatments for neurological disorders.

To stay updated on PaxMedica's latest news and developments, interested investors and shareholders are encouraged to sign up for email alerts on the company's website and follow PaxMedica on Twitter and LinkedIn.

News

PaxMedica Announces Pricing of $7.0 Million Public Offering

Rhea-AI Summary
PaxMedica, Inc. (NASDAQ:PXMD) Announces Pricing of Public Offering of Common Stock and Warrants at $1.30 per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44%
Tags
offering
-
News

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

Rhea-AI Summary
PaxMedica, Inc. (NASDAQ: PXMD) announces its feature in a broadcast via NetworkNewsAudio, highlighting the completion of a type-B meeting with the FDA and positive results from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness. The company is encouraged by the FDA's feedback and is focused on expediting the final steps toward its NDA submission for PAX-101, expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.37%
Tags
none
-
News

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

Rhea-AI Summary
PaxMedica, Inc. (NASDAQ:PXMD) announced a comprehensive business update and financial results for the third quarter of 2023. Key achievements include progress in FDA Type-B meeting for NDA submission of PAX-101, completion of Phase III trials for Human African Trypanosomiasis, strategic acquisition of suramin research assets, and completion of commercial-scale development plan for PAX-101. CEO Howard Weisman highlighted the company's progress and financial report indicated $1.2 million in cash reserves with access to $14.4 million from an equity investment agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.53%
Tags
earnings
News

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

Rhea-AI Summary
PaxMedica, Inc. (NASDAQ:PXMD) announced the publication of research findings in the Annals of General Psychiatry. The study explored the potential of low-dose suramin intravenous infusions as an Autism Spectrum Disorder (ASD) treatment, showing statistically significant improvements in the Clinical Global Impressions-Improvement (CGI-I) scale among the 10 mg/kg suramin arm compared to the placebo group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.54%
Tags
clinical trial
-
News

PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)

Rhea-AI Summary
PaxMedica, a biopharmaceutical company, has engaged Bourne Partners to explore monetization of a Priority Review Voucher (PRV) for the treatment of African Sleeping Sickness. The engagement aims to enhance research and development efforts in neurologic disorders. PaxMedica has decreased the outstanding amount under its convertible note with Lind Global Partners II, LP from $3.68 million to $2.27 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.31%
Tags
none
-
News

PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

Rhea-AI Summary
PaxMedica, a biopharmaceutical company specializing in neurological disorder treatments, has successfully acquired suramin research assets from Rediscovery Life Sciences. These assets will support PaxMedica's efforts to seek approval for PAX-101, a treatment for African Sleeping Sickness. The integration of this data will aid in the submission for the New Drug Application (NDA) and manufacturing production requirements are on track for the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.62%
Tags
acquisition
News

PaxMedica Announces 1-for-17 Reverse Stock Split

Rhea-AI Summary
PaxMedica, Inc. (Nasdaq: PXMD) has completed a 1-for-17 reverse stock split of its common stock. The split-adjusted common stock will begin trading on October 31, 2023, under the symbol 'PXMD'. Each 17 pre-split shares were combined into one post-split share, with no fractional shares issued. Shareholders will receive information from Computershare Trust Corporation, the transfer agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.58%
Tags
none
-
News

PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication

Rhea-AI Summary
PaxMedica's manuscript on low dose suramin infusions for Autism Spectrum Disorder has been accepted for publication in the Annals of General Psychiatry. The research highlights the potential of this treatment and is a significant milestone for the company's dedication to innovative ASD treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.59%
Tags
none
-
News

PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

Rhea-AI Summary
PaxMedica completes type-B meeting with the FDA and receives guidance for NDA filing. Positive results from PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness. NDA expected in second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.59%
Tags
none
News

PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023

Rhea-AI Summary
PaxMedica announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
none

FAQ

What is the current stock price of PAXMEDICA (PXMD)?

The current stock price of PAXMEDICA (PXMD) is $0.058375 as of January 10, 2025.

What is the market cap of PAXMEDICA (PXMD)?

The market cap of PAXMEDICA (PXMD) is approximately 2.8M.

What does PaxMedica specialize in?

PaxMedica specializes in developing anti-purinergic drug therapies for neurological disorders, including Autism Spectrum Disorder (ASD) and Human African Trypanosomiasis (HAT).

What is PAX-101?

PAX-101 is an intravenous suramin formulation developed by PaxMedica, aimed at treating ASD and HAT.

What recent achievements has PaxMedica announced?

PaxMedica recently completed three pivotal registration/validation batches of PAX-101, marking a significant step towards submitting an NDA to the FDA.

What is the significance of PAX-101 for HAT treatment?

If approved, PAX-101 will be the first and only form of suramin available in the U.S. for treating Stage 1 HAT, a fatal disease caused by Trypanosoma brucei rhodesiense.

How is PaxMedica responding to global health crises?

PaxMedica has expedited the provision of PAX-101 to Malawi to address a critical shortage of medications for treating HAT, demonstrating its commitment to global health.

What financial updates has PaxMedica recently provided?

PaxMedica raised approximately $7.0 million through a public offering to repay debts, advance development programs, and support general corporate purposes.

Has PaxMedica transitioned off the NASDAQ stock market?

Yes, PaxMedica has transitioned off the NASDAQ stock market but remains committed to advancing treatments for neurological disorders.

What other conditions is PaxMedica exploring treatments for?

PaxMedica is exploring potential therapeutic applications for related neurologic conditions beyond ASD and HAT.

How can investors stay updated on PaxMedica's latest news?

Investors can sign up for email alerts on PaxMedica's website and follow the company on Twitter and LinkedIn for the latest updates.

What is PaxMedica's mission?

PaxMedica's mission is to develop innovative treatments for neurological disorders, providing hope and support to affected individuals and their families globally.
Stock PXMD logo
PAXMEDICA INC

Nasdaq:PXMD

PXMD Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PXMD Stock Data

2.76M
10.88M
9.01%
4.42%
8.54%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
TARRYTOWN